Abstract Number: 1982 • 2012 ACR/ARHP Annual Meeting
Five Years of Treatment to Target in Early Active Rheumatoid Arthritis: Prevalence and Predictors of Vertebral Fractures
Background/Purpose: Vertebral fractures (VFs) are more common in patients with rheumatoid arthritis (RA) compared to the general population. It is suggested that an appropriate control…Abstract Number: 1983 • 2012 ACR/ARHP Annual Meeting
Comparative Risk of Fracture in Men and Women with Human Immunodeficiency Virus
Background/Purpose: A growing body of evidence suggests that HIV-positive patients have an increased risk of osteoporosis compared to HIV-negative patients, with some studies suggesting a…Abstract Number: 1985 • 2012 ACR/ARHP Annual Meeting
The Effect of Calcium and Vitamin D On Bone Loss in an Epileptic Population
Background/Purpose: Accelerated rate of bone loss leading to osteopenia and osteoporosis is a well recognized adverse effect of long term anticonvulsant use, particularly phenytoin,…Abstract Number: 1986 • 2012 ACR/ARHP Annual Meeting
Impaired Endothelial Function in Post-Menopausal Women with Osteoporosis
Background/Purpose: Although traditionally viewed as separate disease entities that increase in prevalence with aging, accumulating evidence indicates that similar pathophysiological mechanisms may underlie cardiovascular disease…Abstract Number: 1987 • 2012 ACR/ARHP Annual Meeting
A Comparison of Unilateral and Bilateral Hip BMD
Background/Purpose: The utility of bilateral hip dual energy x-ray absorptiometry scanning for identifying low bone mineral density has been a cause of debate. Intraperson differences…Abstract Number: 1988 • 2012 ACR/ARHP Annual Meeting
Zoledronate Efficacy and Safety in Active Paget’s Disease Long-Term Follow-up and Retreatment in Clinical Practice
Background/Purpose: Bisphosphonates are first line therapy in the treatment of Paget's disease (PD). Zoledronate, a third generation bisphosphonate, has showed high efficacy in the inhibition…Abstract Number: 1989 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Vertebral Fractures in Patients with Rheumatoid Arthritis – the Tomorrow Study –
Background/Purpose: Rheumatoid arthritis (RA) is one of the causes for secondary osteoporosis. Osteoporosis as a multifactorial disease might be derived from comorbidity itself, poorer physical…Abstract Number: 1990 • 2012 ACR/ARHP Annual Meeting
Risk of Falling Is Equivalent Between Patients with Rheumatoid Arthritis and Healthy Individuals – the Tomorrow Study-
Background/Purpose: Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falling. The present study…Abstract Number: 1991 • 2012 ACR/ARHP Annual Meeting
Effects of Odanacatib On the Distal Radius and Tibia in Postmenopausal Women: Improvements in Cortical Geometry and Estimated Bone Strength
Background/Purpose: The cathepsin K inhibitor odanacatib (ODN), a novel antiresorptive that preserves bone formation, is currently in phase 3 development for postmenopausal osteoporosis. In a…Abstract Number: 1992 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels
Background/Purpose: Generalized bone loss (osteoporosis or osteopenia) is more common in patients with rheumatoid arthritis (RA) than in the general population. Recent studies suggest that…Abstract Number: 1993 • 2012 ACR/ARHP Annual Meeting
Contribution of Lifestyle Factors to Healthy-Adherer Bias in Prevalent Users of Osteoporotic Drugs
Background/Purpose: Adherence to drug therapy may be a surrogate marker for overall healthy behaviors leading to healthy-adherer bias in epidemiologic studies. This might be particularly…Abstract Number: 1994 • 2012 ACR/ARHP Annual Meeting
The Influence of Percentage Body Fat On Bone Mineral Density in Thin Patients
Background/Purpose: Low Body Mass Index (BMI) is associated with low Bone Mineral Density (BMD) and subsequent risk of fragility fracture. Percentage body fat (%BF), which…Abstract Number: 1995 • 2012 ACR/ARHP Annual Meeting
What Are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs?
Background/Purpose: Pragmatic clinical trials (PCTs) allow for study of real world patients using efficient study designs, facilitating comparative effectiveness research in resource constrained settings. Although…Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…Abstract Number: 1997 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study
Background/Purpose: Denosumab, a fully human monoclonal antibody that specifically targets RANKL to inhibit osteoclast formation, function, and survival, reduces risk for vertebral, non-vertebral, and hip…
ACR Meeting Abstracts